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Abstract
Objectives: To assess the role of the Val66Met polymorphism at the brain-derived neurotrophic 
factor (BDNF) gene on the performance of children and adolescents with bipolar disorder [juvenile 
bipolar disorder (JBD)] on the Wisconsin Card Sorting Test (WCST). Methods: Children and 
adolescents were assessed by the K-SADS-PL and a clinical evaluation for BD and comorbid 
conditions. Manic and depressive symptoms were assessed with the Young Mania Rating Scale 
and the Children Depression Rating Scale – Reviewed. The Val66Met polymorphism at the BDNF 
was genotyped from a blood sample. Patients’ IQ and executive functions were assessed by a 
VWDQGDUGFRJQLWLYHÁH[LELOLW\WHVW:&67Results: Fifty-three subjects were included in the study. 
1RVLJQLÀFDQWGLIIHUHQFHZDVREVHUYHGEHWZHHQWKH9DO9DODQG9DO0HW0HW0HWJURXSVRQDQ\
WCST scores in the MANCOVA (F48,5 = .76; p = .59; Perseverative Errors, p = .66; Nonperseverative 
Errors, p = .58; Categories Completed, p = .34; Attempts to Reach First Category, p=.64; and 
Percentage of Conceptual Level Responses, p = .99). Conclusions: 2XUÀQGLQJVIURPWKLVVDPSOHRI
children and adolescents with BD do not replicate results from studies of adults and suggest the 
existence of differences in the neurobiology of this disorder across the life cycle. Investigations 
RIODUJHUVDPSOHVDUHQHFHVVDU\WRFRQÀUPWKHVHGDWD
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,QWURGXFWLRQ
Children and adolescents with bipolar disorder [juvenile 
bipolar disorder (JBD)] present disabling affective and 
behavioral dysregulation, aggressiveness, and irritability.1,2 
7KHVHVHYHUHPRRGVZLQJVFDXVHVLJQLÀFDQWGHYHORSPHQWDO
impairment. Current studies estimate an occurrence of 
BD in .6-1% of children and adolescents.3 The JBD popula-
tion has a higher propensity of suicide, psychosis, exposure 
to sexual risks and drug use.4-6 JBD is also associated with 
a low symptom remission rate and elevated mood crises 
recurrence.7,8
Neuropsychological studies of adult and pediatric BD 
have helped elucidate the neurobiological underpinnings 
RIWKHGLVRUGHUE\UHYHDOLQJGHÀFLWVLQFRJQLWLYHÁH[LELOLW\
(set shifting), planning, working memory, resistance to 
interference, sustained attention, verbal learning and 
memory.9,102QHRI WKHPRVWFRQVLVWHQWÀQGLQJV LQHDUO\
onset BD (although it is not clear whether it is a trait marker 
LQ-%'LVDGHÀFLWLQFRJQLWLYHÁH[LELOLW\WKDWLVWKHDELOLW\
to modify thinking and behavior in response to changing 
environmental conditions.9-13 This ability may be impaired 
during mood states, when children and adolescents present 
increased energy and excessive involvement in pleasurable 
activities and feel irritable due to the inability to interrupt 
or stop these actions (mania), or during depressive states, 
when positive events do not impact the child’s negative 
affect or thoughts. 
The most widely used test in the assessment of cognitive 
ÁH[LELOLW\LQ%'LVWKH:LVFRQVLQ&DUG6RUWLQJ7HVW:&6714 
A recent investigation of 15 euthymic JBD Type I or II 
VXEMHFWVPHDQDJH\HDUVUHSRUWHGWKH\KDGVLJQLÀ-
cantly higher scores in nonperseverative errors in the WCST 
when compared to healthy controls (n = 15) (p = .038).13 
Another group of investigators compared differences in the 
WCST performance between JBD children and adolescents 
(n = 57) and controls (n = 46) and reported trends for differ-
ences in perseverative errors, nonperseverative errors and 
categories completed subtests in WCST, after controlling 
IRU$WWHQWLRQ'HÀFLW+\SHUDFWLYLW\'LVRUGHU9
The Brain-Derived Neurotrophic Factor (BDNF) is a neu-
rotrophin that plays an important role in neuronal growth, 
survival, and differentiation during development and is 
also involved in learning and memory processes.15,16 The 
association between JBD and BDNF has been documented by 
Geller et al.,16DQGWKHRQO\RWKHUJHQHWRKDYHVLJQLÀFDQW
positive associations is the SLC6A3 (dopamine transporter) 
gene (for a review of genetic association studies in JBD, see 
Mick et al.17). Due to the association between BDNF and BD 
and its participation in the cognitive processes mentioned 
above, a pioneer study addressed the interaction between 
%'1)JHQHSRO\PRUSKLVPVDQGFRJQLWLYHÁH[LELOLW\LQDGXOW
patients with BD (n = 54).18 Patients presenting the Met al-
lele (n = 10) performed more poorly on all of the WCST sub-
tests than patients who were homozygous for the Val allele 
(n = 44). A subsequent study with a larger sample corrobo-
rated the previous conclusions and suggested that the Met 
DOOHOHVSHFLÀFDOO\DIIHFWVWKH:&67UHVXOWVRI%'SDWLHQWV
versus patients with schizophrenia (n = 129) and a control 
group (n = 160). In another study, the Met allele was also 
associated with a poor WCST performance only in patients 
with BD (n = 111).19,20 Further studies of BDNF revealed that 
this SNP , a valine-to-methionine substitution at position 66 
in the coding region (rs6265), reduces activity-dependent 
BDNF secretion through disruption in the BDNF-sortilin 
interaction, which may result in abnormal hippocampal 
structure and function, and consequently alters cognition 
processes.21
'HVSLWH WKH GLIIHUHQFHV LGHQWLÀHG LQ WKH QHXURSV\-
FKRORJLFDOSURÀOHRI WKH-%'VXEMHFWVDFFRUGLQJ WR%'1)
genotype and the potential of BDNF in neurodevelop-
ment, few studies have addressed these issues, and, to 
our knowledge, no previous research has investigated the 
association of cognitive performance in JBD and the BDNF 
gene. Neuropsychological studies may indicate the neural 
FLUFXLWU\ LQYROYHG LQ%'GHÀFLWV WKXVFRQÀUPLQJÀQGLQJV
from neuroimaging investigations suggesting that brain 
areas such as the frontolimbic cortex (ventral prefrontal 
cortex, amygdala, and ventral striatum) are implicated in 
these alterations.12,22
The aim of this investigation was to assess the perfor-
mance of children and adolescents with BD on the WCST 
according to their BDNF Val66Met polymorphism status. Our 
hypothesis is that subjects presenting the Met allele at the 
BDNF will perform less well on the WCST than those who 
present the homozygosity of the Val allele.
Methods
Subjects were recruited from the community through press 
releases, other ongoing JBD studies and the Outpatient 
Program for Children and Adolescents with Bipolar Disorder 
(ProCAB). Inclusion criteria included age (5 to 17 years) and 
diagnoses of BD according to DSM-IV criteria.23 Exclusion 
criteria were diagnosis of Pervasive Developmental 
Disorder, Schizophrenia, Substance Abuse or Substance 
Dependence, or a severe suicide or homicide risk that 
excluded the possibility of outpatient treatment. Written 
informed consent from parents and children’s verbal as-
sent were obtained. This study was approved by the ethi-
cal committee of the Hospital de Clínicas de Porto Alegre 
DSSURYHG DV DQ ,5% E\ WKH 2IÀFH IRU +XPDQ 5HVHDUFK
Protections, United States of America - IRB 00000921), and 
is in accordance with the Helsinki Declaration of 1975. The 
ProCAB is registered at www.clinicaltrials.gov under the 
LGHQWLÀHU1&7
Diagnostic assessment
Diagnostic assessment was conducted in three stages. First, 
a child and adolescent psychiatrist with extensive training 
(GP) interviewed primary caregivers about the presence of 
DSM-IV mood symptoms and the family history of psychi-
atric disorders. Subjects who met the DSM-IV criteria for 
Bipolar I, Bipolar II, or Bipolar NOS then underwent neu-
ropsychological and learning disorder assessments. Also at 
this stage, the K-SADS-PL (Schedule for Affective Disorders 
and Schizophrenia for School-Age Children-Present and 
Lifetime Version) was administered by trained interview-
ers.24 The K-SADS-PL training process was conducted in 
our center and consisted of several seminars about both 
child psychopathology in general and the structure of the 
LQVWUXPHQWOLYHREVHUYDWLRQRIÀYHLQWHUYLHZVSHUIRUPHG
by trained research assistants, and live administration of 
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WKH.6$'63/LQWHUYLHZLQÀYHSDWLHQWVZLWKWKHSUHVHQFH 
of trained observers. Finally, research assistants 
performed reliability analyses based on final KSDAS 
interviews recorded on videotape. Kappa coefficient 
was calculated as .93 for mood disorders in a previ-
ous study.25 Patients and parents answered the mood 
and substance use modules separately and the other 
modules together. A different child and adolescent 
psychiatrist performed a clinical evaluation of BD and 
comorbid conditions using DSM-IV criteria with parents 
and subjects and also checked the positive diagnoses 
derived from K-SADS-PL. Finally, after the entire clinical 
assessment, best estimate diagnoses were achieved through a 
discussion with the entire research group. Priority was 
DOZD\V JLYHQ IRU WKHÀQDO FOLQLFDO GLDJQRVHV IRUPXODWHG 
if a diagnostic disagreement occurred in other stages of 
this process.
Measures
Mania symptoms were assessed with the Young Mania Rating 
Scale (YMRS).26 This instrument is an 11-item scale for the 
assessment of severity of mania symptoms that has similar 
HIÀFLHQF\DFURVVGLIIHUHQWDJHJURXSVLQFOXGLQJ\RXWKDJHG
4-17 years. The YMRS was translated into Portuguese and 
YDOLGDWHG.DSSDLQWUDFODVVFRUUHODWLRQFRHIÀFLHQW
.8).27 The presence and severity of depressive symptoms 
were rated using the Brazilian version of the Children’s 
Depression Rating Scale – Reviewed (CDRS-R).28,29 Mood 
VWDWHV ZHUH GHÀQHG DV IROORZV PDQLD <056   DQG 
&'565   GHSUHVVLRQ <056   DQG &'565   
and euthymia (YMRS < 7 and CDRS-R < 28).29,30 
Genotyping
The genotyping of Val66Met polymorphism was per-
formed with PCR as described by Neves-Pereira et al.31 
Blood (5 mL) was drawn from each subject, and DNA was 
extracted using the high-salt method.32 Subjects were 
genotyped for the BDNF Val66Met SNP that determines 
a valine-to-methionine substitution at position 66 in the 
coding region. The SNP for the GoA (valineomethionine) 
variation at position 758 of the BDNF coding sequence 
was selected from the National Center for Biotechnology 
Information SNP database (reference number rs6265). 
$ ES VHJPHQWZDV DPSOLÀHG E\ 3&5 XVLQJ WKH IRO-
lowing primers: 5-GAGGCTTGACATCATTGGCT-3 and 
5-GTGTACAAGTCTGCGTCCT-3. Target sequences were 
DPSOLÀHGLQDP/UHDFWLRQVROXWLRQFRQWDLQLQJQJ
genomic DNA; 1 U Taq polymerase (Sigma-Aldrich); 20 
mM Tris-HCl (pH 8.4); 50 mM KCl; 1.5 mM MgCl2; 200 mM 
each of dATP, dCTP, dGTP, and dTTP; and 10 pmol of each 
primer. After an initial denaturation of the DNA templates 
for 5 min at 95ºC, 30 cycles were performed, each con-
sisting of 94ºC for 30 s, 60ºC for 30 s, and 72ºC for 30 s. 
After the last cycle, samples were incubated at 72ºC for 
5 min. Samples were then digested overnight with 3 U of 
Eco721 (MBI Fermentas). The fragments were separated 
on a 3.5% agarose gel at 100 V, and fragments were visual-
ized with ethidium bromide. The uncut product size was 
113 bp (allele A), and allele G comprised the cut bands 
of 78 and 35 bp.
Assessment
Intelligence Estimation (IQ). The Vocabulary and Block 
Design subsets of the Wechsler Intelligence Scale for 
Children – Third Version (WISC-III) were used to estimate 
the full scale IQ.33 
The Wisconsin Card Sorting Test (WCST) is a neuropsycho-
logical test that addresses the functions that are primarily 
connected with prefrontal lobe activity, especially cognitive 
ÁH[LELOLW\14 The ability to change a reaction due to unaware-
ness of relevant stimuli is measured by the percentage of 
perseverative errors (WCST-P), the attentional inability to 
avoid distraction is measured by the percentage of non-
perseverative errors (WCST-NP), the ability to utilize new 
information and previous experiences is measured by the 
number of correctly completed categories (WCST-CC), 
the set to the first category measures the ability to 
formulate a logical conception (WCST-1stCAT), and con-
ceptual thinking ability is measured by the percentage 
of conceptual level responses (WCST-%CONC). This set of 
executive functions evaluates abstract thinking and the 
ability to develop problem-solving strategies in response to 
changing stimuli or conditions. The test has been adapted 
for the Brazilian population.34
Statistical analysis
Statistical analyses were performed using the software 
SPSS for Windows, Version 18. Clinical and demographic 
characteristics were considered to be confounding variables 
and were entered as covariables in the models when associ-
ated with both the independent factor (presence or absence 
of the Met allele at the BDNF gene) and the outcome mea-
VXUH:&67VXEWHVWVFRUHVZLWKDÁH[LEOHSYDOXHRI7R
evaluate normal distribution of the variables, the Shapiro–
Wilk test was applied. Differences between the two groups 
of patients were assessed by the Student’s t-test in normal 
distributions and by the nonparametric Mann–Whitney test 
in abnormal distributions. Correlations were tested with 
Spearman’s rho or Pearson’s r according to the sample distri-
EXWLRQV'LIIHUHQFHVEHWZHHQWKH9DO9DODQGWKH9DO0HW
0HW0HWFDUULHUVDWWKH%'1)9DO0HWSRO\PRUSKLVPZHUH
analyzed using Multiple Analysis of Covariance (MANCOVA) 
models, which included terms for covariables. All tests of 
hypotheses used a two-sided alpha = .05.
5HVXOWV
A total of 53 subjects were included in the study. Demographics 
and clinical characteristics, as well as measures of symptom 
VHYHULW\DUHSUHVHQWHGLQ7DEOH1RVLJQLÀFDQWGLIIHUHQFHV
were observed between genotype groups. Due to the design 
of our outpatient program (a naturalistic setting), patients 
usually perform neuropsychological testing while presenting 
symptoms. However, symptom rates or mood states did not 
differ between groups. One-third of the patients (16 out of 
53) were using either mood stabilizers or atypical antipsy-
chotics by the time of evaluation (data available by request).
7KH9DO9DOJHQRW\SHFRPSRVHGRIWKHVDPSOH
VXEMHFWV WKH9DO0HWJHQRW\SH  VXEMHFWV DQG
0HW0HWRQO\VXEMHFW,QPDOHVXEMHFWVQ 
SUHVHQWHGWKH9DO9DOJHQRW\SHSUHVHQWHGWKH9DO0HW
DQGSUHVHQWHGWKH0HW0HW,QWKHIHPDOHJURXSQ 
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Table 1 Demographics and clinical characteristics of the sample.
Val/Val (n = 40) Val/Met (n = 12) or
Met/Met (n = 1)
0HDQ6' 0HDQ6' SYDOXH
Age 11.90 ± 2.61 10.07 ± 3.01 .07
Duration of disorder 5.03 ± 2.87 5.25 ± 2.54 .84
Intelligence quotient 86.27 ± 14 90.25 ± 16.2 .45
CGAS 47.78 ± 11.96 51.00 ± 10.80 .38
Assessment scale
YMRS 24.41 ± 13.45 27.22 ± 9.08 .46
CDRS-R 41.84 ± 14.52 39.55 ± 14.8 .68
Frequency: n (%) Frequency: n (%)
Socio-economical status C: 25 (62.5%) C: 11 (84.6%) .37
Gender Male 26 (65%) 7 (53.8%) .52
Ethnicity Caucasian 34 (85%) 12 (92.3%) .6
Bipolar disorder subtype Type I 26 (65%) 11 (84.6%) .41
Type II 6 (15%) 1 (7.7%)
NOS 8 (20%) 1 (7.7%)
Comorbidities ADHD 35 (87.5%) 10 (77%) .39
Disruptive disorders 25 (62.5%) 8 (61.5%) .5
Anxiety disorders 21 (52.5%) 5 (38.5%) 1.00
Enuresis 7 (17.5%) 4 (30.8%) .43
Current medication use 10 (25%) 6 (46.1%) .18
CGAS: Children's Global Assessment Scale; YMRS: Young Mania Rating Scale; CDRS-R: Children's Depression Rating Scale, Revised;  
1261RWRWKHUZLVHVSHFLÀHG$'+'$WWHQWLRQ'HÀFLW+\SHUDFWLYLW\'LVRUGHU
Table 2 Comparison of the Val66Met polymorphism at the BDNF gene in the results of the Wisconsin Card Sorting Test in 
children and adolescents with bipolar disorder.
9DO9DOQ  Val/Met (n = 9) or
Met/Met (n = 1)
:LVFRQVLQ&DUG6RUWLQJ7HVW 0HDQ6' 0HDQ6' SYDOXH 3DUWLDO 
(WD6TXDUHG
Percentage of Perseverative Errors 20.39 ± 10.95 18.90 ± 10.64 .66 < .01
Percentage of Nonperseverative Errors 22.37 ± 12.24 24.50 ± 12.68 .58 < .01
Number of Correctly Completed Categories 3 ± 1.98 3.60 ± 2.01 .34 .02
Set to the First Category 34.07 ± 35.67 25.5 ± 18.22 .64 < .01
Percentage of Conceptual Level Responses 44.15 ± 20.36 44.61 ± 24.05 .99 < .01
* Multivariate Analysis of Variance (F48,5 = .76; p = .59- Partial Eta Squared = .08).
9DO9DOZDVIRXQGLQVXEMHFWV9DO0HWLQSDWLHQWVDQG
WKHUHZHUH QR0HW0HW FDVHV$V WKH0HW0HW JHQRW\SH 
DWWKH%'1)ZDVSUHVHQWLQRQO\RQHVXEMHFWWKH0HW0HW
DQG9DO0HWFDUULHUJURXSVZHUHPHUJHGDQGFODVVLÀHGLQWR
Met carriers, as has been performed in other investigations.18 
The distributions of genotypes did not deviate from Hardy–
:HLQEHUJHTXLOLEULXPŲ2 = 2.74, p = .26).
The Wisconsin Card Sorting Test scores presented asym-
metrical distribution, and their values were normalized using 
log transformation. Data from WCST-T1C and WCST-%CLR 
IURPÀYHSDWLHQWVZDVQRWDYDLODEOHDQGWKH\ZHUHWKXVH[-
cluded from the MANCOVA. Current use of medication was not 
associated to any WCST subtest scores (WCST-P p = .32; 
WCST-NP p = .83; WCST-CC p = .31; WCST-%CONC p = .28; WCST-
1stCAT p = .90) and was not included in the MANCOVA model.
1RVLJQLÀFDQWGLIIHUHQFHZDVREVHUYHGEHWZHHQWKH9DO
9DODQG9DO0HW0HW0HWJURXSVDQGWKH:&67UHVXOWVLQWKH
MANCOVA (F48,5 = .76; p = .59, Partial Eta Squared = .08), 
RU:&67VSHFLÀFFDWHJRULHV3HUVHYHUDWLYH(UURUVS 
Partial Eta Squared < .01; Nonperseverative Errors, p = .58, 
Partial Eta Squared < .01; Categories Completed, p = .34, 
Partial Eta Squared = .02; Attempts to Reach First Category, 
p = .64, Partial Eta Squared < .01; and Percentage of 
Conceptual Level Responses, p = .99, Partial Eta Squared < 
.01). Results are presented in Table 2. Even though comor-
bidity with ADHD was not considered to be a confounding 
variable in our comprehensive approach, its inclusion in the 
PRGHOGLGQRWFKDQJHRXUÀQGLQJVVLJQLÀFDQWO\S 
'LVFXVVLRQ
7KLVZDVWKHÀUVWLQYHVWLJDWLRQWRDVVHVVWKHUROHRIDJHQH
on neuropsychological tests in children and adolescents with 
bipolar disorder. We were not able to detect any differences 
LQD WHVWRI FRJQLWLYHÁH[LELOLW\ :&67DQG WKH9DO0HW
polymorphism at the BDNF gene. 
Attentional ability to avoid distraction, to utilize new 
information and previous experiences, to formulate a logi-
cal conception, to form a conceptual thinking and inability 
to change reaction due to unawareness of relevant stimuli 
were not mediated by the presence of the Met allele at the 
BDNF. Although robust data exist suggesting that children 
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DQGDGROHVFHQWVZLWK%'KDYHGHÀFLWVLQH[HFXWLYHIXQFWLRQV
such as abstract thinking, problem-solving skills, and cogni-
WLYHÁH[LELOLW\ZKLFKFDQUHVXOWLQPDODGDSWLYHEHKDYLRUWKH
previously documented reduction in activity-dependent BDNF 
VHFUHWLRQ GLG QRW WUDQVODWH LQWR DGGLWLRQDO FRJQLWLYH ÁH[-
LELOLW\GHÀFLWVLQRXUVDPSOH9,10,217KLVÀQGLQJZDVVXUSULVLQJ
due to previous results in studies with adult populations. In 
adults with bipolar disorder, the poorest performance in the 
Wisconsin Card Sorting Test was observed for BDNF Met allele 
carriers when compared subjects with BD, schizophrenia and 
typically developing adults.18-20 Moreover, other researchers 
have not found an association between the BDNF Val66Met 
polymorphism and performance in the WCST in a quantitative 
transmission disequilibrium test (QTDT) analyses in adults 
with schizophrenia,35 or in a comparison of homicidal and 
non-homicidal male adults with schizophrenia.36 As this is a 
pioneer study in children and adolescents, we cannot draw 
DJHVSHFLÀFFRPSDULVRQV
Although BDNF has been widely associated with the neuro-
biology of adult BD, it is possible that its measurable effects 
on neuropsychological functions are not present in children 
due to the ongoing development of frontolimbic areas (and 
consequently executive functions) through adolescence, as 
has been suggested by neuropsychological and neuroimaging 
studies of JBD.22,37,38 This speculation is partially supported 
in our sample by the positive correlation between age and 
performance in all WCST categories. It is also possible that 
consecutive mood episodes may be responsible for progres-
sive cognitive deterioration, as decreased BDNF peripheral 
levels are present in adults with late-stage BD, as compared 
to patients in the early stages of the disorder.39 Longitudinal 
studies that include measurement of BDNF peripheral levels in 
children and adolescents may provide an answer to this issue.
We cannot rule out that WCST was not able to detect 
FRJQLWLYH ÁH[LELOLW\ GHÀFLWV EHFDXVH H[HFXWLYH IXQFWLRQ
weaknesses in JBD are milder and less consistent than in 
other childhood disorders such as ADHD.38 In addition, some 
patients were using mood stabilizers and antipsychotics, and 
we cannot quantify the effect of these drugs on the test re-
VXOWV+RZHYHUFXUUHQWQHXURSV\FKRORJLFDOÀQGLQJVUHJDUGLQJ
juvenile bipolar disorder persist regardless of the state of 
WKHLOOQHVVRUPHGLFDWLRQVWDWXVDOWKRXJKVXFKÀQGLQJVDUH
limited and inconclusive.40 Futures studies should address 
these issues through the use of different neuropsychological 
tests and on drug-naïve subjects. 
2XUÀQGLQJVVKRXOGEHFRQVLGHUHGLQOLJKWRIVRPHOLPL-
tations. The Met allele frequency in our sample was lower 
than in the other previous studies, as was the percentage of 
females in our sample. However, no change was found when 
the gender variable was included in the model. Although 
our sample size was comparable with the original study 
in adults (n = 54), we cannot completely exclude the pos-
sibility that lack of power affected our results. Our effect 
size estimates for all WCST scores (eta partial squares) were 
H[WUHPHO\VPDOOWKLVÀQGLQJVXJJHVWVQRUHOHYDQWHIIHFWVRI
this polymorphism on the WCST scores. In addition, to reach 
80% power in all WCST subtests, with the means and standard 
deviations found in our sample, the minimum sample size we 
ZRXOGQHHGIRUVWDWLVWLFDOVLJQLÀFDQFHZRXOGEHVXE-
jects in WCST-PE, 31,005 subjects in WCST-NP, 3,339 in WCST-
CC, 1,680 in WCST-1stCAT, and 100,800 in WCST-%CLR. These 
H[WUHPHO\ HOHYDWHG QXPEHUV VXSSRUW WKH QRQVLJQLÀFDQFH
of the differences between the genotypes in our sample. 
Statistical control for potential sociodemographic and clinical 
confounding variables was broad and strongly suggests that 
RXUÀQGLQJVZHUHQRWLQÁXHQFHGE\RWKHUYDULDEOHV
Further investigations with larger samples, including 
a more comprehensive battery of neuropsychological testes, 
may provide a better understanding of the neurobiological 
pathways that are involved in this highly disabling disorder .
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